WO1998011437B1 - Bibliotheques de marquage d'affinite avec groupes partants marques - Google Patents
Bibliotheques de marquage d'affinite avec groupes partants marquesInfo
- Publication number
- WO1998011437B1 WO1998011437B1 PCT/US1997/016435 US9716435W WO9811437B1 WO 1998011437 B1 WO1998011437 B1 WO 1998011437B1 US 9716435 W US9716435 W US 9716435W WO 9811437 B1 WO9811437 B1 WO 9811437B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- affinity
- group
- amino acid
- composition
- amino acids
- Prior art date
Links
- 238000002372 labelling Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 claims abstract 11
- 238000000034 method Methods 0.000 claims abstract 9
- 229940024606 amino acid Drugs 0.000 claims 13
- 235000001014 amino acid Nutrition 0.000 claims 13
- 150000001413 amino acids Chemical class 0.000 claims 13
- 229960004441 tyrosine Drugs 0.000 claims 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 3
- 239000004473 Threonine Substances 0.000 claims 3
- 229960003767 alanine Drugs 0.000 claims 3
- 229960001153 serine Drugs 0.000 claims 3
- 229960002898 threonine Drugs 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 2
- 150000008574 D-amino acids Chemical class 0.000 claims 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 150000008575 L-amino acids Chemical class 0.000 claims 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 2
- -1 O-methyl-substituted serine Chemical class 0.000 claims 2
- 102000015636 Oligopeptides Human genes 0.000 claims 2
- 108010038807 Oligopeptides Proteins 0.000 claims 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 2
- 229960003121 arginine Drugs 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 229940065734 gamma-aminobutyrate Drugs 0.000 claims 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 2
- 229960002989 glutamic acid Drugs 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 2
- 229960002743 glutamine Drugs 0.000 claims 2
- 229960003136 leucine Drugs 0.000 claims 2
- 229930182817 methionine Natural products 0.000 claims 2
- 229960004452 methionine Drugs 0.000 claims 2
- 229960005190 phenylalanine Drugs 0.000 claims 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 2
- 150000003588 threonines Chemical class 0.000 claims 2
- 229960004799 tryptophan Drugs 0.000 claims 2
- 150000003668 tyrosines Chemical class 0.000 claims 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 229960005261 aspartic acid Drugs 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 125000002228 disulfide group Chemical group 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 229960002449 glycine Drugs 0.000 claims 1
- 150000002466 imines Chemical class 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 125000005328 phosphinyl group Chemical group [PH2](=O)* 0.000 claims 1
- 125000005499 phosphonyl group Chemical group 0.000 claims 1
- 229960002429 proline Drugs 0.000 claims 1
- 150000003355 serines Chemical class 0.000 claims 1
- 150000007970 thio esters Chemical class 0.000 claims 1
- 229960004295 valine Drugs 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 108091008324 binding proteins Proteins 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000012503 blood component Substances 0.000 abstract 1
- 239000002532 enzyme inhibitor Substances 0.000 abstract 1
- 229940125532 enzyme inhibitor Drugs 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
Abstract
L'invention concerne des procédés et des compositions permettant d'identifier des composés présentant une affinité vis à vis d'un site cible. Selon ledit procédé, le groupe à affinité est un groupe partant provenant d'une fonctionnalité réactive pouvant former une liaison covalente avec le site cible. Il est possible de combiner le composé comprenant le site cible avec la bibliothèque et de procéder à un dosage concernant la composition obtenue des groupes partants. Les groupes partants présentant la concentration la plus élevée peuvent être identifiés comme les groupes ayant la plus haute affinité de liaison vis à vis du site cible. Les composés sélectionnés peuvent ensuite être utilisés pour marquer la molécule cible, en particulier lorsque la molécule cible est trouvée naturellement dans un mélange complexe, tel qu'un liquide physiologique, par exemple le sang. Grâce à un marquage d'affinité in vivo, la durée de vie d'entités physiologiquement actives peut être grandement prolongée par le fait qu'elles se lient à des composants du sang à longue vie. L'entité liée par covalence peut également servir d'antagoniste ou d'agoniste de protéines de liaison particulières ou bien d'inhibiteur enzymatique.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU43518/97A AU4351897A (en) | 1996-09-16 | 1997-09-16 | Affinity labeling libraries with tagged leaving groups |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71475496A | 1996-09-16 | 1996-09-16 | |
US08/714,754 | 1996-09-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998011437A1 WO1998011437A1 (fr) | 1998-03-19 |
WO1998011437B1 true WO1998011437B1 (fr) | 1998-06-11 |
Family
ID=24871322
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/016435 WO1998011437A1 (fr) | 1996-09-16 | 1997-09-16 | Bibliotheques de marquage d'affinite avec groupes partants marques |
Country Status (3)
Country | Link |
---|---|
US (1) | US6403324B1 (fr) |
AU (1) | AU4351897A (fr) |
WO (1) | WO1998011437A1 (fr) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1199566B1 (fr) * | 1997-11-07 | 2008-08-27 | ConjuChem Biotechnologies Inc. | Méthodes de criblage de bibliothèques de marqueurs à affinité |
CA2305597C (fr) | 1997-11-07 | 2008-07-29 | Conjuchem Inc. | Marqueurs d'affinite pour la serum-albumine humaine |
CA2330611A1 (fr) | 1998-05-22 | 1999-12-02 | The Board Of Trustees Of The Leland Stanford Junior University | Molecules bifonctionnelles et therapies basees sur celles-ci |
US6335155B1 (en) * | 1998-06-26 | 2002-01-01 | Sunesis Pharmaceuticals, Inc. | Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules |
US6998233B2 (en) | 1998-06-26 | 2006-02-14 | Sunesis Pharmaceuticals, Inc. | Methods for ligand discovery |
US6919178B2 (en) | 2000-11-21 | 2005-07-19 | Sunesis Pharmaceuticals, Inc. | Extended tethering approach for rapid identification of ligands |
US6887470B1 (en) * | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
CA2501421A1 (fr) | 1999-05-17 | 2000-11-23 | Conjuchem Inc. | Exendin-4 a longue duree d'action |
US20040266673A1 (en) * | 2002-07-31 | 2004-12-30 | Peter Bakis | Long lasting natriuretic peptide derivatives |
US20090175821A1 (en) * | 1999-05-17 | 2009-07-09 | Bridon Dominique P | Modified therapeutic peptides with extended half-lives in vivo |
US7601691B2 (en) | 1999-05-17 | 2009-10-13 | Conjuchem Biotechnologies Inc. | Anti-obesity agents |
US6514500B1 (en) * | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
EP1229924A4 (fr) | 1999-11-19 | 2004-12-15 | Univ Leland Stanford Junior | Molecules bifonctionnelles ciblees et therapies basees sur celles-ci |
US6887842B1 (en) | 1999-11-19 | 2005-05-03 | The Board Of Trustees Of The Leland Stanford Junior University | Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug |
US7220552B1 (en) | 1999-11-19 | 2007-05-22 | The Board Of Trustees Of The Leland Stanford Junior University | Bifunctional molecules and their use in the disruption of protein-protein interactions |
US20010051348A1 (en) | 2000-01-28 | 2001-12-13 | Lee Chee Wee | Novel ligands and methods for preparing same |
US20020045194A1 (en) * | 2000-04-10 | 2002-04-18 | Cravatt Benjamin F. | Proteomic analysis |
PT1360202E (pt) | 2001-02-16 | 2008-09-01 | Conjuchem Biotechnologies Inc | Peptídeo do tipo glucagon 2 (glp-2) de longa duração para o tratamento de doenças e distúrbios gastrointestinais |
US7927579B2 (en) * | 2003-01-17 | 2011-04-19 | Advanced Proteome Therapeutics, Inc | Tandem analyses of noncovalently driven effectors for modulatory mapping of activities of protein sites |
PT2100904E (pt) * | 2004-04-23 | 2010-09-24 | Conjuchem Biotechnologies Inc | Fase sólida para utilização num método para a purificação de conjugados de albumina |
US8039432B2 (en) * | 2005-11-09 | 2011-10-18 | Conjuchem, Llc | Method of treatment of diabetes and/or obesity with reduced nausea side effect |
CA2634495A1 (fr) * | 2005-12-22 | 2007-06-28 | Conjuchem Biotechnologies Inc. | Procede de production de conjugues d'albumine preformes et agent therapeutique |
US20090099074A1 (en) * | 2007-01-10 | 2009-04-16 | Conjuchem Biotechnologies Inc. | Modulating food intake |
US20090186819A1 (en) * | 2007-12-11 | 2009-07-23 | Marieve Carrier | Formulation of insulinotropic peptide conjugates |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5266684A (en) | 1988-05-02 | 1993-11-30 | The Reagents Of The University Of California | Peptide mixtures |
US5650489A (en) | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
US6087186A (en) | 1993-07-16 | 2000-07-11 | Irori | Methods and apparatus for synthesizing labeled combinatorial chemistry libraries |
AU7516694A (en) * | 1993-07-30 | 1995-02-28 | Affymax Technologies N.V. | Biotinylation of proteins |
EP0639585A1 (fr) | 1993-08-20 | 1995-02-22 | Banyu Pharmaceutical Co., Ltd. | Inhibiteur d'élastase |
US5571681A (en) | 1994-03-10 | 1996-11-05 | The Scripps Research Institute | Chemical event selection by suicide substrate conjugates |
US5738996A (en) | 1994-06-15 | 1998-04-14 | Pence, Inc. | Combinational library composition and method |
US5834318A (en) | 1995-05-10 | 1998-11-10 | Bayer Corporation | Screening of combinatorial peptide libraries for selection of peptide ligand useful in affinity purification of target proteins |
-
1997
- 1997-09-16 AU AU43518/97A patent/AU4351897A/en not_active Abandoned
- 1997-09-16 WO PCT/US1997/016435 patent/WO1998011437A1/fr active Application Filing
-
1998
- 1998-03-13 US US09/042,234 patent/US6403324B1/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998011437B1 (fr) | Bibliotheques de marquage d'affinite avec groupes partants marques | |
DeLange et al. | Calf and pea histone IV: II. The complete amino acid sequence of calf thymus histone IV; presence of ε-N-acetyllysine | |
Akiyama et al. | Synthetic peptides competitively inhibit both direct binding to fibroblasts and functional biological assays for the purified cell-binding domain of fibronectin. | |
Waite | Mussel glue from Mytilus californianus Conrad: a comparative study | |
Gregory et al. | The primary structure of human urogastrone | |
Krieg et al. | Identification of the 40 S ribosomal protein S6 phosphorylation sites induced by cycloheximide. | |
Aitken et al. | Identification of the NH2-terminal blocking group of calcineurin B as myristic acid | |
Rawal et al. | Structural specificity of substrate for S-adenosylmethionine protein arginine N-methyltransferases | |
Ozawa et al. | The reactive site of trypsin inhibitors | |
Jones et al. | Extension of the amino acid sequence of a lysine-rich histone | |
Gorman et al. | Structural features of glutamine substrates for transglutaminases. Role of extended interactions in the specificity of human plasma factor XIIIa and of the guinea pig liver enzyme. | |
EP1456662B1 (fr) | Procede pour detecter des auto-anticorps chez des patients souffrant de polyarthrite rhumatoïde | |
Shapira et al. | Encephalitogenic fragment of myelin basic protein: amino acid sequence of bovine, rabbit, guinea pig, monkey, and human fragments | |
AU4829999A (en) | Methods for rapidly identifying small organic ligands | |
CA2277832A1 (fr) | Peptides cycliques se fixant a un recepteur de l'activateur de plasminogene de type urokinase | |
TAKAHARA et al. | Purification and characterization of peptidylarginine deiminase from rabbit skeletal muscle | |
DE3244030A1 (de) | Chromogene verbindungen, verfahren zu ihrer herstellung und ihre verwendung | |
McFadden et al. | Chemical conversion of aspartyl peptides to isoaspartyl peptides. A method for generating new methyl-accepting substrates for the erythrocyte D-aspartyl/L-isoaspartyl protein methyltransferase. | |
WO1995003327A3 (fr) | Peptides de neutralisation de la toxicite du lipide a | |
Frøyshov et al. | On the biosynthesis of bacitracin by a soluble enzyme complex from Bacillus licheniformis | |
Perham et al. | The Determination of the Order of Lysine‐containing: Tryptic Peptides of Proteins by Diagonal Paper Electrophoresis A Carboxyl‐terminal Sequence for Pepsin | |
Morino et al. | Primary structure of pyridoxal phosphate binding site in the mitochondrial and extramitochondrial aspartate aminotransferases from pig heart muscle. Chymotryptic peptides | |
König et al. | The amino acid sequence of the peptide moiety of the pseudomurein from Methanobacterium thermoautotrophicum | |
Ramshaw et al. | The amino acid sequence of plastocyanin from Solanum tuberosum L.(potato) | |
JP2009544638A (ja) | タンパク質結合メトトレキサート誘導体、及びそれを含有する薬剤 |